These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

628 related articles for article (PubMed ID: 25421015)

  • 21. Efficacy and safety of canagliflozin over 52 weeks in patients with type 2 diabetes mellitus and chronic kidney disease.
    Yale JF; Bakris G; Cariou B; Nieto J; David-Neto E; Yue D; Wajs E; Figueroa K; Jiang J; Law G; Usiskin K; Meininger G;
    Diabetes Obes Metab; 2014 Oct; 16(10):1016-27. PubMed ID: 24965700
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Mechanistic evaluation of the effect of sodium-dependent glucose transporter 2 inhibitors on delayed glucose absorption in patients with type 2 diabetes mellitus using a quantitative systems pharmacology model of human systemic glucose dynamics.
    Mori-Anai K; Tashima Y; Nakada T; Nakamaru Y; Takahata T; Saito R
    Biopharm Drug Dispos; 2020 Nov; 41(8-9):352-366. PubMed ID: 33085977
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effects of hydrochlorothiazide on the pharmacokinetics, pharmacodynamics, and tolerability of canagliflozin, a sodium glucose co-transporter 2 inhibitor, in healthy participants.
    Devineni D; Vaccaro N; Polidori D; Rusch S; Wajs E
    Clin Ther; 2014 May; 36(5):698-710. PubMed ID: 24726680
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pharmacodynamics, efficacy and safety of sodium-glucose co-transporter type 2 (SGLT2) inhibitors for the treatment of type 2 diabetes mellitus.
    Scheen AJ
    Drugs; 2015 Jan; 75(1):33-59. PubMed ID: 25488697
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Metabolic Effects of an SGLT2 Inhibitor (Dapagliflozin) During a Period of Acute Insulin Withdrawal and Development of Ketoacidosis in People With Type 1 Diabetes.
    Herring RA; Shojaee-Moradie F; Garesse R; Stevenage M; Jackson N; Fielding BA; Mendis A; Johnsen S; Umpleby AM; Davies M; Russell-Jones DL
    Diabetes Care; 2020 Sep; 43(9):2128-2136. PubMed ID: 32641376
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pharmacokinetics, Pharmacodynamics, and Safety of Canagliflozin in Japanese Patients with Type 2 Diabetes Mellitus.
    Iijima H; Kifuji T; Maruyama N; Inagaki N
    Adv Ther; 2015 Aug; 32(8):768-82. PubMed ID: 26280756
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Population Pharmacokinetic- Pharmacodynamic Analysis to Characterize the Effect of Empagliflozin on Renal Glucose Threshold in Patients With Type 1 Diabetes Mellitus.
    Mondick J; Riggs M; Kaspers S; Soleymanlou N; Marquard J; Nock V
    J Clin Pharmacol; 2018 May; 58(5):640-649. PubMed ID: 29251772
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Better response to the SGLT2 inhibitor dapagliflozin in young adults with type 2 diabetes.
    Nakamura Y; Nagai Y; Terashima Y; Nishine A; Ishii S; Kato H; Ohta A; Tanaka Y
    Expert Opin Pharmacother; 2015; 16(17):2553-9. PubMed ID: 26479189
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effect of canagliflozin on renal threshold for glucose, glycemia, and body weight in normal and diabetic animal models.
    Liang Y; Arakawa K; Ueta K; Matsushita Y; Kuriyama C; Martin T; Du F; Liu Y; Xu J; Conway B; Conway J; Polidori D; Ways K; Demarest K
    PLoS One; 2012; 7(2):e30555. PubMed ID: 22355316
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Dapagliflozin twice daily or once daily: effect on pharmacokinetics and urinary glucose excretion in healthy subjects.
    Tang W; Reele S; Hamer-Maansson JE; Parikh S; de Bruin TW
    Diabetes Obes Metab; 2015 Apr; 17(4):423-5. PubMed ID: 25511685
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effect of canagliflozin, a sodium glucose co-transporter 2 (SGLT2) inhibitor, on bacteriuria and urinary tract infection in subjects with type 2 diabetes enrolled in a 12-week, phase 2 study.
    Nicolle LE; Capuano G; Ways K; Usiskin K
    Curr Med Res Opin; 2012 Jul; 28(7):1167-71. PubMed ID: 22548646
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clinical Pharmacokinetic, Pharmacodynamic, and Drug-Drug Interaction Profile of Canagliflozin, a Sodium-Glucose Co-transporter 2 Inhibitor.
    Devineni D; Polidori D
    Clin Pharmacokinet; 2015 Oct; 54(10):1027-41. PubMed ID: 26041408
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effect of Ipragliflozin (ASP1941), a novel selective sodium-dependent glucose co-transporter 2 inhibitor, on urinary glucose excretion in healthy subjects.
    Veltkamp SA; Kadokura T; Krauwinkel WJ; Smulders RA
    Clin Drug Investig; 2011 Dec; 31(12):839-51. PubMed ID: 21877761
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effects of the SGLT2 inhibitor dapagliflozin on proteinuria in non-diabetic patients with chronic kidney disease (DIAMOND): a randomised, double-blind, crossover trial.
    Cherney DZI; Dekkers CCJ; Barbour SJ; Cattran D; Abdul Gafor AH; Greasley PJ; Laverman GD; Lim SK; Di Tanna GL; Reich HN; Vervloet MG; Wong MG; Gansevoort RT; Heerspink HJL;
    Lancet Diabetes Endocrinol; 2020 Jul; 8(7):582-593. PubMed ID: 32559474
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Single-dose Pharmacokinetics and Pharmacodynamics of Canagliflozin, a Selective Inhibitor of Sodium Glucose Cotransporter 2, in Healthy Indian Participants.
    Devineni D; Polidori D; Curtin C; Stieltjes H; Tian H; Wajs E
    Clin Ther; 2016 Jan; 38(1):89-98.e1. PubMed ID: 26687552
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A Randomized Crossover Trial of Mixed Meal Tolerance Test Response in People with Type 1 Diabetes on Insulin Pump Therapy and YG1699 or Dapagliflozin.
    Lapuerta P; Urbina S; He J; Wittle A; Li C; Li T; Wang H; Hompesch M
    Clin Pharmacol Ther; 2024 Jun; 115(6):1383-1390. PubMed ID: 38456487
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinical pharmacokinetics and pharmacodynamics of dapagliflozin, a selective inhibitor of sodium-glucose co-transporter type 2.
    Kasichayanula S; Liu X; Lacreta F; Griffen SC; Boulton DW
    Clin Pharmacokinet; 2014 Jan; 53(1):17-27. PubMed ID: 24105299
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effect of hepatic or renal impairment on the pharmacokinetics of canagliflozin, a sodium glucose co-transporter 2 inhibitor.
    Devineni D; Curtin CR; Marbury TC; Smith W; Vaccaro N; Wexler D; Vandebosch A; Rusch S; Stieltjes H; Wajs E
    Clin Ther; 2015 Mar; 37(3):610-628.e4. PubMed ID: 25659911
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Evaluating the costs of glycemic response with canagliflozin versus dapagliflozin and empagliflozin as add-on to metformin in patients with type 2 diabetes mellitus in the United Arab Emirates.
    Schubert A; Buchholt AT; El Khoury AC; Kamal A; Taieb V
    Curr Med Res Opin; 2017 Jun; 33(6):1155-1163. PubMed ID: 28323512
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Evaluating SGLT2 inhibitors for type 2 diabetes: pharmacokinetic and toxicological considerations.
    Scheen AJ
    Expert Opin Drug Metab Toxicol; 2014 May; 10(5):647-63. PubMed ID: 24387329
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 32.